Andrew C. Lauck - 30 Jul 2026 Form 4 Insider Report for Strata Critical Medical, Inc. (SRTA)

Reporting relationship: Director
Issuer ticker: SRTA
Reported as of: 30 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Aug 2026, 16:06:41 UTC
Prior SEC filing: 05 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Melissa M. Tomkiel, as attorney-in-fact for Andrew C. Lauck

Key filing fact

Andrew C. Lauck filed Form 4 for Strata Critical Medical, Inc. (SRTA) on 03 Aug 2026.

Key facts

This page summarizes Andrew C. Lauck's Form 4 filing for Strata Critical Medical, Inc. (SRTA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Aug 2026, 16:06.

Change

Previous filing in this sequence was filed on 05 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001970526 Primary reporting owner

LAUCK ANDREW

Relationship: Director
Address: C/O STRATA CRITICAL MEDICAL, INC., 666 THIRD AVENUE, 25TH FLOOR, NEW YORK
Signature: /s/ Melissa M. Tomkiel, as attorney-in-fact for Andrew C. Lauck
Signature date: 03 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SRTA transaction

Class A common stock, $0.0001 par value per share

Award

Transaction value
Shares: +35,260
Change %: +26%
Price: $0.000000^*
Shares after: 170,902
Date: 30 Jul 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents a grant of Restricted Stock Units ("RSUs"), which will be settled in shares of the Issuer's common stock upon vesting. 100% of the RSUs will become vested on the date of the Issuer's 2027 Annual Meeting of Stockholders.